{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T14:50:12Z","timestamp":1787237412419,"version":"build-2736575974"},"reference-count":6,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,10,28]]},"DOI":"10.7759\/cureus.72592","type":"journal-article","created":{"date-parts":[[2024,10,29]],"date-time":"2024-10-29T02:14:12Z","timestamp":1730168052000},"source":"Crossref","is-referenced-by-count":3,"title":["A Case of Advanced Extramammary Paget\u2019s Disease With a High Tumor Mutation Burden That Showed Partial Lymph Node Regression With Pembrolizumab"],"prefix":"10.7759","author":[{"given":"Ken","family":"Horisaki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoki","family":"Taki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shoichiro","family":"Mori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mao","family":"Okumura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masashi","family":"Akiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2019.00160","article-title":"Updates on the systemic treatment of advanced non-melanoma skin cancer","volume":"6","author":"Tanese K","year":"2019","unstructured":"Tanese K, Nakamura Y, Hirai I, Funakoshi T. Updates on the systemic treatment of advanced non-melanoma skin cancer. Front Med (Lausanne). 2019, 6:160. 10.3389\/fmed.2019.00160","journal-title":"Front Med (Lausanne)"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2021.7148","article-title":"Evidence-based clinical practice guidelines for extramammary Paget disease","volume":"8","author":"Kibbi N","year":"2022","unstructured":"Kibbi N, Owen JL, Worley B, et al.. Evidence-based clinical practice guidelines for extramammary Paget disease. JAMA Oncol. 2022, 8:618-28. 10.1001\/jamaoncol.2021.7148","journal-title":"JAMA Oncol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30445-9","article-title":"Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study","volume":"21","author":"Marabelle A","year":"2020","unstructured":"Marabelle A, Fakih M, Lopez J, et al.. Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. Lancet Oncol. 2020, 21:1353-65. 10.1016\/S1470-2045(20)30445-9","journal-title":"Lancet Oncol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.16898","article-title":"Treatment of high tumor mutation burden metastatic extramammary Paget disease with an anti-PD-1 antibody","volume":"50","author":"Nakayama Y","year":"2023","unstructured":"Nakayama Y, Ogata D, Wada S, et al.. Treatment of high tumor mutation burden metastatic extramammary Paget disease with an anti-PD-1 antibody. J Dermatol. 2023, 50:e396-7. 10.1111\/1346-8138.16898","journal-title":"J Dermatol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.17101","article-title":"Unfavorable efficacy of pembrolizumab for advanced extramammary Paget's disease with high tumor mutation burden after failure of taxane-based regimens","volume":"51","author":"Koizumi S","year":"2024","unstructured":"Koizumi S, Doi R, Aitake U, et al.. Unfavorable efficacy of pembrolizumab for advanced extramammary Paget's disease with high tumor mutation burden after failure of taxane-based regimens. J Dermatol. 2024, 51:e203-4. 10.1111\/1346-8138.17101","journal-title":"J Dermatol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2024.113530","article-title":"Safety profile of pembrolizumab monotherapy based on an aggregate safety evaluation of 8937 patients","volume":"199","author":"Brahmer JR","year":"2024","unstructured":"Brahmer JR, Long GV, Hamid O, et al.. Safety profile of pembrolizumab monotherapy based on an aggregate safety evaluation of 8937 patients. Eur J Cancer. 2024, 199:113530. 10.1016\/j.ejca.2024.113530","journal-title":"Eur J Cancer"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/309411-a-case-of-advanced-extramammary-pagets-disease-with-a-high-tumor-mutation-burden-that-showed-partial-lymph-node-regression-with-pembrolizumab","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,29]],"date-time":"2024-10-29T02:14:14Z","timestamp":1730168054000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/309411-a-case-of-advanced-extramammary-pagets-disease-with-a-high-tumor-mutation-burden-that-showed-partial-lymph-node-regression-with-pembrolizumab"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,28]]},"references-count":6,"URL":"https:\/\/doi.org\/10.7759\/cureus.72592","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10,28]]}}}